ES2086949T3 - Material polihidroxilico reticulado para liberacion de farmaco enzimaticamente controlada. - Google Patents

Material polihidroxilico reticulado para liberacion de farmaco enzimaticamente controlada.

Info

Publication number
ES2086949T3
ES2086949T3 ES93915611T ES93915611T ES2086949T3 ES 2086949 T3 ES2086949 T3 ES 2086949T3 ES 93915611 T ES93915611 T ES 93915611T ES 93915611 T ES93915611 T ES 93915611T ES 2086949 T3 ES2086949 T3 ES 2086949T3
Authority
ES
Spain
Prior art keywords
amylase
alpha
cross
crosslinked
drug release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915611T
Other languages
English (en)
Inventor
Mircea A Mateescu
Yves Dumoulin
Louis Cartilier
Vincent Lenaerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labopharm Inc
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Application granted granted Critical
Publication of ES2086949T3 publication Critical patent/ES2086949T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION TIENE QUE VER CON UNA UNIDAD DE DOSIS FARMACEUTICA DE LIBERACION LENTA DE SOLIDO. MAS ESPECIFICAMENTE, LA INVENCION SE DIRIGE A UN COMPRIMIDO PREPARADO MEDIANTE COMPRESION DIRECTA DE AMILOSA ENTRECRUZADA (CLA) QUE TIENE UN GRADO DE ENTRECRUZAMIENTO DEFINIDO, ALFA-AMILASA Y UN AGENTE FARMACEUTICO. LA PRESENCIA DEL LA AMILOSA ENTRECRUZADA PERMITE UNA LIBERACION ININTERRUMPIDA DEL FARMACO, MIENTRAS LA ALFA-AMILASA PERMITE LA MODULACION DEL TIEMPO DE LIBERACION. EN OTRAS PALABRAS, EL TIEMPO DE LIBERACION DEL FARMACO ESTA EN FUNCION DE LA CANTIDAD DE ALFA-AMILASA EN EL COMPRIMIDO. LA CANTIDAD DE ALFA-AMILASA SE DEFINE EN TERMINOS DE UNIDADES ENZIMATICAS.
ES93915611T 1992-07-24 1993-07-22 Material polihidroxilico reticulado para liberacion de farmaco enzimaticamente controlada. Expired - Lifetime ES2086949T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91976292A 1992-07-24 1992-07-24

Publications (1)

Publication Number Publication Date
ES2086949T3 true ES2086949T3 (es) 1996-07-01

Family

ID=25442612

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915611T Expired - Lifetime ES2086949T3 (es) 1992-07-24 1993-07-22 Material polihidroxilico reticulado para liberacion de farmaco enzimaticamente controlada.

Country Status (18)

Country Link
EP (1) EP0651634B1 (es)
JP (1) JP3647859B2 (es)
KR (1) KR100304997B1 (es)
AT (1) ATE137668T1 (es)
AU (1) AU668198B2 (es)
CA (1) CA2140032C (es)
CZ (1) CZ283395B6 (es)
DE (1) DE69302580T2 (es)
ES (1) ES2086949T3 (es)
FI (1) FI950301A0 (es)
GR (1) GR3020476T3 (es)
HU (1) HU221591B (es)
MX (1) MX9304459A (es)
NO (1) NO308024B1 (es)
NZ (1) NZ254048A (es)
PL (1) PL173249B1 (es)
RU (1) RU2136270C1 (es)
WO (1) WO1994002121A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US6077537A (en) * 1997-05-21 2000-06-20 Warner-Lambert Company Non-sedating acrivastine product
US5989589A (en) * 1997-10-24 1999-11-23 Cartilier; Louis Cross-linked cellulose as a tablet excipient
US6660303B2 (en) 1999-12-06 2003-12-09 Edward Mendell & Co. Pharmaceutical superdisintegrant
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
EP1946780B1 (en) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
AR082167A1 (es) 2010-07-14 2012-11-14 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3181998A (en) * 1960-08-12 1965-05-04 Joseph L Kanig Tablet disintegration
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
SE420565B (sv) * 1974-06-06 1981-10-19 Pharmacia Ab Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel
DE3721574A1 (de) * 1987-06-30 1989-01-12 Kettelhack Riker Pharma Gmbh Arzneimittel in form von pellets mit enzymatisch kontrollierter arzneistoff-freisetzung

Also Published As

Publication number Publication date
CA2140032C (en) 1999-01-26
CA2140032A1 (en) 1994-02-03
FI950301A (fi) 1995-01-24
DE69302580T2 (de) 1996-09-26
GR3020476T3 (en) 1996-10-31
NO308024B1 (no) 2000-07-10
EP0651634A1 (en) 1995-05-10
CZ15295A3 (en) 1995-09-13
HUT75673A (en) 1997-05-28
PL307234A1 (en) 1995-05-15
AU668198B2 (en) 1996-04-26
RU2136270C1 (ru) 1999-09-10
NO950251D0 (no) 1995-01-23
EP0651634B1 (en) 1996-05-08
JPH08502036A (ja) 1996-03-05
KR100304997B1 (ko) 2002-04-24
JP3647859B2 (ja) 2005-05-18
PL173249B1 (pl) 1998-02-27
HU9500197D0 (en) 1995-03-28
FI950301A0 (fi) 1995-01-24
NZ254048A (en) 1995-09-26
DE69302580D1 (de) 1996-06-13
HU221591B (hu) 2002-11-28
WO1994002121A1 (en) 1994-02-03
MX9304459A (es) 1994-04-29
AU4555993A (en) 1994-02-14
ATE137668T1 (de) 1996-05-15
CZ283395B6 (cs) 1998-04-15
NO950251L (no) 1995-01-23

Similar Documents

Publication Publication Date Title
ES2086949T3 (es) Material polihidroxilico reticulado para liberacion de farmaco enzimaticamente controlada.
FI954232A0 (fi) Siiloitettu amyloosi sideaineena/hajotusaineena tableteissa
NO20004208L (no) Fornettet stivelse med høyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasøytiske midler
PT954290E (pt) Comprimido farmaceutico de libertacao controlada contendo um suporte a base de amilose reticulada e de hidroxipropilmetilcelulose.
ATE448797T1 (de) Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
NO20001042L (no) Oftalmiske preparater med forsinket frigivelse inneholdende vannoppløselige medikamenter
ATE187640T1 (de) Arzneimittel in tablettenform mit verzögerter wirkstoffabgabe auf basis von hochmolekularen polysaccharidgranulaten
RU95107880A (ru) Твердая фармацевтическая форма
DE59504270D1 (de) Retardtablette mit einem gehalt an diclofenac-na
DE69225053D1 (de) Zusammensetzungen auf der basis von collagen zur kontrollierten arzneistoffreisetzung
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
KR890700025A (ko) 진통제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 651634

Country of ref document: ES